Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.42
CLSN's Cash to Debt is ranked lower than
70% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. CLSN: 2.42 )
Ranked among companies with meaningful Cash to Debt only.
CLSN' s Cash to Debt Range Over the Past 10 Years
Min: 0.45  Med: 24.09 Max: No Debt
Current: 2.42
Equity to Asset 0.28
CLSN's Equity to Asset is ranked lower than
84% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CLSN: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
CLSN' s Equity to Asset Range Over the Past 10 Years
Min: -1.05  Med: 0.56 Max: 0.97
Current: 0.28
-1.05
0.97
F-Score: 3
Z-Score: -10.21
M-Score: -3.58
WACC vs ROIC
17.71%
-306.28%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4092.80
CLSN's Operating margin (%) is ranked lower than
88% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. CLSN: -4092.80 )
Ranked among companies with meaningful Operating margin (%) only.
CLSN' s Operating margin (%) Range Over the Past 10 Years
Min: -4943  Med: -2116.58 Max: -75.43
Current: -4092.8
-4943
-75.43
Net-margin (%) -4434.20
CLSN's Net-margin (%) is ranked lower than
90% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. CLSN: -4434.20 )
Ranked among companies with meaningful Net-margin (%) only.
CLSN' s Net-margin (%) Range Over the Past 10 Years
Min: -5098.8  Med: -1405.68 Max: -67.41
Current: -4434.2
-5098.8
-67.41
ROE (%) -126.17
CLSN's ROE (%) is ranked lower than
85% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. CLSN: -126.17 )
Ranked among companies with meaningful ROE (%) only.
CLSN' s ROE (%) Range Over the Past 10 Years
Min: -6771.43  Med: -93.27 Max: 257.55
Current: -126.17
-6771.43
257.55
ROA (%) -48.84
CLSN's ROA (%) is ranked lower than
66% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. CLSN: -48.84 )
Ranked among companies with meaningful ROA (%) only.
CLSN' s ROA (%) Range Over the Past 10 Years
Min: -217.17  Med: -44.46 Max: 121.96
Current: -48.84
-217.17
121.96
ROC (Joel Greenblatt) (%) -2823.16
CLSN's ROC (Joel Greenblatt) (%) is ranked lower than
74% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. CLSN: -2823.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLSN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4101.97  Med: -1418.77 Max: -115.63
Current: -2823.16
-4101.97
-115.63
EBITDA Growth (3Y)(%) -34.40
CLSN's EBITDA Growth (3Y)(%) is ranked lower than
84% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CLSN: -34.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLSN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.6  Med: -4.3 Max: 39.1
Current: -34.4
-57.6
39.1
EPS Growth (3Y)(%) -33.10
CLSN's EPS Growth (3Y)(%) is ranked lower than
80% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CLSN: -33.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLSN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.2  Med: -6 Max: 33.9
Current: -33.1
-48.2
33.9
» CLSN's 10-Y Financials

Financials (Next Earnings Date: 2017-03-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CLSN Guru Trades in Q4 2015

Jim Simons 25,648 sh (New)
Chuck Royce Sold Out
» More
Q1 2016

CLSN Guru Trades in Q1 2016

Jim Simons 27,648 sh (+7.80%)
» More
Q2 2016

CLSN Guru Trades in Q2 2016

Jim Simons 51,848 sh (+87.53%)
» More
Q3 2016

CLSN Guru Trades in Q3 2016

Jim Simons 137,985 sh (+166.13%)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ABIO, AMEX:MSTX, NAS:CYAN, NAS:CSBR, NAS:MRNS, NAS:VKTX, NAS:PRAN, NAS:SBOT, AMEX:HEB, OTCPK:BLEVF, OTCPK:ONCYF, NAS:MBVX, NAS:TKAI, NAS:STEM, NAS:CERU, OTCPK:NXTTF, OTCPK:FENCF, OTCPK:PRGB, OTCPK:ENZN, NAS:CYCC » details
Traded in other countries:CBOB.Germany,
Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.

Celsion Corp was founded in 1982 and is a Delaware corporation. The Company is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's product include ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). The Company's pipeline also includes GEN-1 a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence. It is also working to develop and commercialize oncology therapies based on its technologies by developing novel therapeutics for cancer treatment. The Company faces competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to regulation by the FDA and foreign regulatory agencies.

Ratios

vs
industry
vs
history
P/B 1.70
CLSN's P/B is ranked higher than
73% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: 3.57 vs. CLSN: 1.70 )
Ranked among companies with meaningful P/B only.
CLSN' s P/B Range Over the Past 10 Years
Min: 1.25  Med: 2.15 Max: 167.59
Current: 1.7
1.25
167.59
P/S 34.00
CLSN's P/S is ranked lower than
72% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. CLSN: 34.00 )
Ranked among companies with meaningful P/S only.
CLSN' s P/S Range Over the Past 10 Years
Min: 2.23  Med: 21.06 Max: 585.38
Current: 34
2.23
585.38
Current Ratio 0.92
CLSN's Current Ratio is ranked lower than
89% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CLSN: 0.92 )
Ranked among companies with meaningful Current Ratio only.
CLSN' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.41 Max: 104.65
Current: 0.92
0.3
104.65
Quick Ratio 0.92
CLSN's Quick Ratio is ranked lower than
86% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. CLSN: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
CLSN' s Quick Ratio Range Over the Past 10 Years
Min: 0.3  Med: 3.76 Max: 104.65
Current: 0.92
0.3
104.65
Days Sales Outstanding 3.65
CLSN's Days Sales Outstanding is ranked higher than
93% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. CLSN: 3.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLSN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.65  Med: 107.18 Max: 2190
Current: 3.65
3.65
2190

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -41.20
CLSN's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. CLSN: -41.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLSN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.2  Med: -27.8 Max: 1.9
Current: -41.2
-66.2
1.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.62
CLSN's Price/Median PS Value is ranked lower than
82% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CLSN: 1.62 )
Ranked among companies with meaningful Price/Median PS Value only.
CLSN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 4.14 Max: 4324.13
Current: 1.62
0.13
4324.13
Earnings Yield (Greenblatt) (%) -168.58
CLSN's Earnings Yield (Greenblatt) (%) is ranked lower than
99.99% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. CLSN: -168.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLSN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -188.13  Med: 715.7 Max: 887.9
Current: -168.58
-188.13
887.9

More Statistics

Revenue (TTM) (Mil) $0.50
EPS (TTM) $ -0.90
Beta2.09
Short Percentage of Float2.22%
52-Week Range $0.62 - 2.31
Shares Outstanding (Mil)26.08

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 1 1
EPS ($) -0.89 -0.63 -0.55 -0.46
EPS w/o NRI ($) -0.89 -0.63 -0.55 -0.46
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 

More From Other Websites
8:06 am Celsion announces that the independent DSMB has completed its safety review of data from the... Dec 01 2016
Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer Dec 01 2016
Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA... Nov 30 2016
Celsion Corporation Announces Presentation of Results from Independent NIH Analysis of ThermoDox®... Nov 29 2016
CELSION CORP Financials Nov 18 2016
ETFs with exposure to Celsion Corp. : November 16, 2016 Nov 16 2016
Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016 Nov 15 2016
Celsion downgraded by Maxim Group Nov 10 2016
Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly... Nov 10 2016
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 10 2016
Celsion Corporation Reports Third Quarter 2016 Financial Results and Provides Business Update Nov 10 2016
Q3 2016 Celsion Corp Earnings Release - Time Not Supplied Nov 10 2016
Celsion Corporation to Hold Third Quarter 2016 Financial Results Conference Call on Thursday,... Nov 08 2016
Celsion Corporation Announces Issuance of Two New U.S. Patents for its GEN-1 Immuno-Oncology Product Nov 04 2016
Celsion Corporation to Hold Third Quarter 2016 Financial Results Conference Call on Thursday,... Nov 03 2016
Celsion Presents Data on ThermoDox® plus Optimized RFA in Intermediate Primary Liver Cancer at the... Oct 31 2016
ETF’s with exposure to Celsion Corp. : October 13, 2016 Oct 13 2016
Celsion Announces Collaboration with the Children’s Research Institute to Evaluate the Use of... Oct 11 2016
Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer Sep 15 2016
ETF’s with exposure to Celsion Corp. : September 12, 2016 Sep 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)